[이데일리 김진수 기자] Ildong Pharmaceutical announced on the 6th that it has received approval from the Ministry of Food and Drug Safety for phase 1 clinical trial of ‘ID110521156’, a new drug candidate in the field of metabolic diseases with a mechanism of GLP-1 receptor agonist. Ildong Pharmaceutical Headquarters. (Photo = Ildong Pharmaceutical) Ildong Pharmaceutical plans to evaluate the tolerability, safety, and pharmacokinetic characteristics of ‘ID110521156’ in healthy adults. Ildong Pharmaceutical plans to develop an oral new drug targeting type 2 diabetes and obesity in the future according to the progress of commercialization work such as clinical development.
‘ID110521156’ is a GLP-1 receptor agonist drug that acts as a GLP-1 hormone analogue that regulates blood sugar levels by inducing insulin secretion in the body. The GLP-1 hormone is produced in beta cells of the pancreas and is known to be involved in the synthesis and secretion of insulin in the body, the reduction of blood sugar level, the regulation of gastrointestinal motility, and the suppression of appetite.
‘ID110521156’ is a novel compound that has the same function as the GLP-1 hormone. It has a low molecular weight and is stable compared to biological drugs such as peptides.
Ildong Pharmaceutical plans to promote the development of an oral dosage form drug that has advantages in terms of marketability and ease of administration while being differentiated from existing drugs mainly focused on injections by utilizing the differences in efficacy, safety, and stability derived from the structural characteristics of the substance.
An official from Ildong Pharmaceutical explained, “In the efficacy evaluation and toxicity evaluation of ‘ID110521156’ using disease animal models, we have confirmed its effectiveness in insulin secretion and blood sugar control, as well as its superior safety compared to competing drugs in the same series.”
“Currently, discussions on partnerships, such as out-licensing, are actively underway with a number of global pharmaceutical companies,” he said. “We have completed patent registration or application for
2023-09-06 06:01:18
#Ildong #Pharmaceuticals #GLP1 #receptor #agonist #received #clinical #approval #Ministry #Food #Drug #Safety
